Long-term pharmacotherapy with beta-blockers, calcium channel blockers, or ACE inhibitors reverses left ventricular hypertrophy by 8% to 14% in patients with cardiac hypertrophy.
Does long-term pharmacotherapy with beta-blockers, calcium channel blockers, or ACE inhibitors improve left ventricular hypertrophy, diastolic function, and coronary reserve in patients with hypertensive heart disease?
ACE inhibitors and calcium channel blockers are particularly effective at reversing left ventricular hypertrophy and improving diastolic function and coronary reserve in hypertensive heart disease.
The prehypertrophic state of hypertensive heart disease is characterized by morphologic changes (interstitial fibrosis, increase in intramyocardial arteriolar wall thickness) as well as by functional alterations (diastolic dysfunction, decrease in coronary reserve). These changes most probably represent the earliest cardiac end-organ lesions that can clinically be detected. In cardiac hypertrophy, long-term (9-12 months) pharmacotherapy with beta-blockers, calcium channel blockers, or ACE inhibitors reverses left ventricular hypertrophy by 8% to 14%, whereas marked improvement in coronary reserve and diastolic dysfunction is achieved by calcium blocker and preferably by ACE inhibitors.
Strauer et al. (Wed,) conducted a review in Hypertensive heart disease with cardiac hypertrophy. Pharmacotherapy (beta-blockers, calcium channel blockers, or ACE inhibitors) was evaluated on Reversal of left ventricular hypertrophy, coronary reserve, and diastolic dysfunction. Long-term pharmacotherapy with beta-blockers, calcium channel blockers, or ACE inhibitors reverses left ventricular hypertrophy by 8% to 14% in patients with cardiac hypertrophy.